Impact Factor
Global reach, higher impact
Review Frailty and [177Lu]Lu-PSMA-617 therapy: tools and strategies for older men with metastatic castration-resistant prostate cancer Full text PDF
Research Paper Dual-metallic porphyrinic MOFs with pH/ROS-responsive release for antibacterial and antioxidant therapy of diabetic infected wounds Full text PDF
Research Paper A multimodal pipeline for the identification and diagnostic immunoPET validation of hepatocellular carcinoma targets for radiotheranostic development Full text PDF
Research Paper An αvβ6/αvβ8-targeting peptibody inhibits integrin-dependent TGFβ activation, enables tumor-selective cytotoxic delivery, and synergizes with PD-L1 immune checkpoint blockade Full text PDF
Research Paper Radiocopper in BCMA-targeted immunotheranostics of myeloma Full text PDF
Research Paper Novel nastorazepide-based radioligands demonstrate effective cholecystokinin-2 receptor targeting with potential for theranostic applications Full text PDF
Issue 12; 2026
Founding Editor-in-Chief:
Prof. Xiaoyuan (Shawn) Chen, PhD
Profile
Theranostics publishes innovative research articles reflecting the fields of in vitro diagnostics and prognostics, in vivo molecular imaging, molecular therapeutics, image-guided therapy, biosensors, system biology and translational medicine, personalized medicine and a broad spectrum of biomedical research that can be applied to future theranostic applications.
- Theranostics is indexed by Science Citation Index (SCI) and MEDLINE. (Full index information)
- Full texts of articles in PubMed Central and Europe PMC. Abstracts in PubMed.
- (For NIH-funded researchers) Save time by submitting your paper to us - this journal is in full compliance with NIH Public Access Requirement.
Radiolabeled gastrin antagonists are emerging as a new tool for the diagnosis and treatment of cholecystokinin-2 receptor (CCK2R) expressing tumors such as medullary thyroid carcinoma and small cell lung cancer, overcoming limitations of agonist-based ligands. In this study, the CCK2R antagonist nastorazepide (Z-360) was used as a targeting scaffold in combination with either a peptidic (NPP) or a hydrophilic polysaccharide (NPS) linker and the chelators ...